The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Research Report 2025

Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1883827

No of Pages : 85

Ask Your Query

Report Description
Table of Content

Synopsis
Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) market is projected to reach US$ million in 2030, increasing from US$ million in 2023, with the CAGR of % during the period of 2024 to 2030.
Key manufacturers engaged in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) industry include Gilead, Bristol Myers Squibb, AbbVie, Johnson & Johnson, Boehringer Ingelheim, Merck and Kawin Technology, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % volume of Hepatitis C Treatment Direct-Acting Antiviral (DAA) were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Hepatitis C Treatment Direct-Acting Antiviral (DAA) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2019-2023) and forecast calculation (2024-2030), aims to help readers to get a comprehensive understanding of global Hepatitis C Treatment Direct-Acting Antiviral (DAA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Gilead
Bristol Myers Squibb
AbbVie
Johnson & Johnson
Boehringer Ingelheim
Merck
Kawin Technology
Segment by Type
Pangenotypic
Genotype-Specific or Polygenotypic
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hepatitis C Treatment Direct-Acting Antiviral (DAA) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Overview
1.1 Product Overview and Scope of Hepatitis C Treatment Direct-Acting Antiviral (DAA)
1.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Segment by Type
1.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value Comparison by Type (2024-2030)
1.2.2 Pangenotypic
1.2.3 Genotype-Specific or Polygenotypic
1.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Segment by Application
1.3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size Estimates and Forecasts
1.4.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue 2019-2030
1.4.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales 2019-2030
1.4.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Competition by Manufacturers
2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Average Price by Manufacturers (2019-2024)
2.4 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Product Type & Application
2.7 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Competitive Situation and Trends
2.7.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hepatitis C Treatment Direct-Acting Antiviral (DAA) Players Market Share by Revenue
2.7.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Retrospective Market Scenario by Region
3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2019-2030
3.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2019-2024
3.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2025-2030
3.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2019-2030
3.3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2019-2024
3.3.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2025-2030
3.4 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country
3.4.1 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2019-2030)
3.4.3 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country
3.5.1 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2019-2030)
3.5.3 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country
3.6.1 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2019-2030)
3.6.3 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country
3.7.1 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2019-2030)
3.7.3 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2019-2030)
4.1.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2019-2024)
4.1.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2025-2030)
4.1.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Type (2019-2030)
4.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2019-2030)
4.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2019-2024)
4.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2025-2030)
4.2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Type (2019-2030)
4.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2019-2030)
5.1.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2019-2024)
5.1.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2025-2030)
5.1.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Application (2019-2030)
5.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2019-2030)
5.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2019-2024)
5.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2025-2030)
5.2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Application (2019-2030)
5.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead
6.1.1 Gilead Corporation Information
6.1.2 Gilead Description and Business Overview
6.1.3 Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.1.5 Gilead Recent Developments/Updates
6.2 Bristol Myers Squibb
6.2.1 Bristol Myers Squibb Corporation Information
6.2.2 Bristol Myers Squibb Description and Business Overview
6.2.3 Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.2.5 Bristol Myers Squibb Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Corporation Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Kawin Technology
6.6.1 Kawin Technology Corporation Information
6.6.2 Kawin Technology Description and Business Overview
6.6.3 Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Industry Chain Analysis
7.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Production Mode & Process
7.4 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales and Marketing
7.4.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Channels
7.4.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Distributors
7.5 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Customers
8 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Dynamics
8.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Industry Trends
8.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Drivers
8.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Challenges
8.4 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}